These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8576606)

  • 1. Intracellular localization of dapsone and rifampicin in skin and nerve of multidrug treated leprosy patients.
    Save MP; Shetty VP; Antia NH
    Indian J Lepr; 1995; 67(3):273-84. PubMed ID: 8576606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up study of pauci-bacillary leprosy on-multi-drug regimen.
    Ramanan R; Manglani PR; Ghorpade A; Bhagoliwal SK
    Indian J Lepr; 1987; 59(1):50-3. PubMed ID: 3611861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
    Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
    Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug therapy in leprosy.
    Manglani PR; Arif MA
    J Indian Med Assoc; 2006 Dec; 104(12):686-8. PubMed ID: 17474286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results.
    Kroger A; Pannikar V; Htoon MT; Jamesh A; Katoch K; Krishnamurthy P; Ramalingam K; Jianping S; Jadhav V; Gupte MD; Manickam P
    Trop Med Int Health; 2008 May; 13(5):594-602. PubMed ID: 18346026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of multidrug therapy on leprosy in Baroda district (Gujarat).
    Chopra NK; Agarwal JS; Pandya PG
    Indian J Lepr; 1989 Apr; 61(2):179-89. PubMed ID: 2746026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two multidrug fixed-dosage treatment regimens with multibacillary leprosy patients.
    Gallo ME; Alvim MF; Nery JA; Albuquerque EC; Sarno EN
    Indian J Lepr; 1996; 68(3):235-45. PubMed ID: 8889609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
    Rao PN; Suneetha S; Pratap DV
    Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy.
    Shetty VP; Wakade AV; Ghate S; Pai VV; Ganapati R; Antia NH
    Int J Lepr Other Mycobact Dis; 2003 Sep; 71(3):210-7. PubMed ID: 14608816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-histopathological study of multidrug therapy in indeterminate leprosy.
    Kar PK; Jha PK; Panaych JS; Snehi PS
    Indian J Lepr; 1990; 62(1):98-103. PubMed ID: 2358708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of MDT in multibacillary leprosy.
    Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
    Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of drug regimen in lepromatous leprosy--II.
    Ramu G; Sreevatsa
    Lepr India; 1983 Apr; 55(2):200-8. PubMed ID: 6195452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
    Biswas S; Mondal KK
    Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
    Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.